Home / Transcripts / OptimizeRx Corporation (OPRX) · May 12, 2026

OptimizeRx Corporation (OPRX) Earnings Call Transcript

May 12, 2026

NASDAQ US Health Care Health Care Technology earnings 29 min

Earnings Call Speaker Segments

Steve Silvestro executive
#1

Thanks, operator, and good afternoon to all of you who've joined for the first quarter 2026 earnings call. We turned in a strong beginning to the year, beating consensus estimates on both the top and bottom line. First quarter revenue came in at $19.8 million, while adjusted EBITDA reached $3.3 million. We're happy with how the quarter went, but the wider operating landscape for healthcare technology keeps changing. When we look at the revenue we have under contract, it's still softer than what we saw a year ago. The main reason appears to be disruption over the near to medium term connected to the most favored nation pricing situation from last year, plus broader macroeconomic conditions. Those factors are causing customers to be more careful about how they allocate budgets and how long contracts run, and in some instances they're pushing back the timing and reducing the scope of campaigns. That said, let us be clear: we don't think these pressures are going to stick around. As a matter of fact, we've already seen solid progress with a number of large manufacturers, bringing their spend levels back up, and the problem now affects fewer areas than it did before. The movement in life sciences toward engagement powered by digital data is speeding up over the long haul, and OptimizeRx is in a strong spot to benefit from that expansion. We keep witnessing positive indicators that our customers are adopting and expanding over the long term. Our DAAP offering, which is enabled by AI, posted 60% growth during the first quarter, underscoring sustained product market fit along with customer adoption. Yet another of our leading pharmaceutical clients has kept widening how it uses point of prescribe solutions spanning several oncology brands. What started out as focused engagement inside particular indications has turned into a scaled deployment across multiple brands, propelled by measurable gains in prescriber engagement and campaign performance; expansion of this kind highlights our capacity to grow within large enterprise accounts. Med tech is showing the same kind of traction for us. There, we're getting more customers to adopt DAAP so they can spot and engage prescriber groups with high value. What began as pilot programs is now growing into engagements worth several million dollars, which further confirms that our growth model can be repeated. Operationally, things are holding up quite well — we keep getting steady confirmation that our platform works for both pharma and med tech clients. Beyond that, we're building out our footprint among mid-tier and long-tail life science firms, and we view that segment as a sizable opportunity for OptimizeRx that hasn't been fully tapped yet. On top of that, we're steadily moving more of our revenue toward subscription-based arrangements, especially in DAAP. Our DAAP subscription revenue rose 45% as well, driven by our AI-enabled DAAP solution, which grew during the first quarter; this shift marks a significant move toward greater revenue visibility and a more resilient, predictable financial model down the road. Even with clear growth in our business, macroeconomic pressures remain, and our view of the full year is less clear. Because of that, we're revising our full year 2026 guidance to reflect a more cautious revenue outlook. Revenue is now projected to land between $95 million and $100 million. The important point is that adjusted EBITDA guidance remains unchanged at $21 million-$25 million. That number captures two things: how solid our operating model is, and the cost optimization work we've already set in motion. To bring our cost structure in line with what's happening around us, we've prioritized strategic investments, trimmed discretionary spending, rolled out new agentic technology tools inside our own operations to gain efficiency, and taken advantage of how scalable our platform is, given that most of its costs are fixed. Through these moves, we anticipate cutting cash operating expenses by roughly $3 million on an annualized basis, which includes about $1 million of savings in 2026 as an in-year benefit, and that figure leaves out any severance related impacts. Beyond that, the steps we've taken to improve gross margin continue to pay off, and for the full year we now expect that figure to come in somewhere in the high 60% range. The refinancing of our term loan that we completed recently has left us in a stronger financial position as well. Ed will cover more of the details later on in our presentation, but in short, we anticipate that the new term loan will reduce our interest expense by about 625 basis points. We want to express our thanks to Blue Torch for being a solid partner throughout the past two years. As we shared in a recent announcement, we continue to take the key steps needed to expand our platform capabilities and our connectivity into the wider ecosystem. At this moment, we are allowing demand side platforms that manage over 80% of digital promotional dollars to plug straight into OptimizeRx's proprietary EHR network. This technical upgrade to our platform, combined with the broadening of our go-to-market strategy, amounts to a major opportunity for the business, and we expect it to produce outsized growth throughout the planning season and on into 2027. Once DSPs have programmatic access via our network, media buyers are able to launch scalable point-of-care and point-of-prescribe campaigns within the programmatic workflows they already rely on, which in effect establishes OptimizeRx as a supply-side platform for marketers seeking to reach healthcare providers directly inside the clinical workflow. Right now, our estimate is that traditional HCP marketing efforts account for under 10% of the inventory we have available throughout the network. Programmatic activation—which is how pharma media agencies typically prefer to purchase these solutions—could, in our view, drive utilization considerably higher as time goes on. Because programmatic has already taken the bulk of media spending in other verticals, we believe there's a substantial chance for this channel to grow and, over the long run, perhaps reach a size similar to that of our existing HCP business. This topic has been raised previously, so let me touch on artificial intelligence briefly and restate our position: we don't see AI as something that disrupts our business. Instead, we view it as something that could speed things up. When our customers find efficiencies in areas such as content creation, we anticipate those savings will be put back into execution and engagement—areas where OptimizeRx is especially well-positioned. Last, even though we're dealing with near-term pressures, our fundamental value proposition hasn't changed, and our long-term outlook is still very optimistic. We're deeply integrated into how our customers complete their work. The returns we deliver are significant and measurable. The market we operate in is large, vibrant, and growing, which provides substantial potential over the long term. That said, I'd like to pass things to Ed Stelmakh, our CFSO, so he can walk us through the numbers. Ed?

Edward Stelmakh executive
#2

Appreciate that, Steve. Hello, everyone, and good afternoon. As with all of our quarterly calls, we issued a press release earlier today that details how we performed in Q1, which closed on March 31st, 2026. That document is available to read or download through the investor relations portion of our site. Further details will also appear in the 10-Q we'll be filing shortly. For Q1 2026, we brought in $19.8 million in revenue. That compares with $21.9 million recognized during the same quarter of 2025, so we're looking at a 10% decrease. A few things contributed to that drop, as we see it: lower-margin managed services fell off, one of our big client accounts brought in less revenue, and budgets were being allocated more conservatively, with shorter program commitments as well — a result of most-favored-nation pricing plus other macroeconomic pressures. When we look at expenses for the quarter that closed March 31st, 2026, they declined $4.6 million versus the prior year, largely because cost of revenue and G&A both came down. A favorable product mix drove the reduction in cost of revenue, because during this quarter we generated no revenue from DTC managed services, and we also benefited from a favorable mix of channel partners. The margin optimization strategies we've rolled out across the past 12 months, we believe, are still delivering substantial gains. Consequently, for the entirety of 2026 we now anticipate gross margins will normalize within the upper 60% range. For the three months that ended March 31st, 2026, GAAP net loss came in narrower at $0.5 million, equal to $0.03 per basic and diluted share, versus a net loss of $2.2 million, or $0.12 per basic and diluted share, for the three months in the same period of 2025. When you look at things on a non-GAAP basis, net income for Q1 2026 rose to $2.7 million, which works out to $0.14 per diluted share. In the same period a year earlier, non-GAAP net income was $1.5 million, or $0.08 per diluted share. Adjusted EBITDA, meanwhile, grew to $3.3 million for the quarter, up from $1.5 million in the first quarter of 2025. Operating cash flow for Q1 landed at -$0.5 million, driven mainly by payments during the first quarter of 2026 tied to 2025 bonuses as well as sales commissions from the fourth quarter of 2025. As for our cash balance, it stood at $20.2 million when the quarter closed, versus $23.4 million as of December 31st, 2025. When Q1 wrapped up, we were carrying $23.6 million in debt, and during that quarter we retired $2.7 million in principal. Then, after the first quarter ended, we moved our term loan from Blue Torch Capital over to Fifth Third Bank, giving us a term loan of $25 million that's fully drawn plus a $10 million revolver we can tap. Right now, the interest rate on that Fifth Third term loan sits at SOFR plus 2.25%, compared with the SOFR plus 8.5% we were paying Blue Torch Capital — that works out to roughly $1.5 million saved on interest expense each year. With the solid working capital base we have, we feel good about our capacity to support operations and the strategic initiatives that matter most, while we keep pushing toward becoming a consistent Rule of 40 business. Now, on to the KPIs for Q1 2026. For the top 20 pharma manufacturers, average revenue is now around $2.8 million, and in Q1 2026 those top 20 accounted for 52% of what we do. Our net revenue retention rate is still a robust 110%. At the same time, revenue per FTE reached $801,000, which is above the $710,000 figure from Q1 2025. What these numbers show is how sticky our solutions are with current customers, plus how much leverage our operating model offers. Steve already mentioned this, but despite genuine expansion in the business, macroeconomic headwinds remain, and our ability to see clearly across the entire year has diminished. That being the case, and consistent with what Steve said before, we're updating our 2026 full year outlook to capture a more conservative top-line perspective. What we now expect is revenue in the range of $95 million to $100 million, and we continue to believe operating leverage will drive adjusted EBITDA to land somewhere between $21 million and $25 million. Finally, we still expect revenue to be weighted toward the latter portion of the year, roughly a 40/60 split; with that said, I'll turn things back over to Steve. Steve?

Steve Silvestro executive
#3

Thank you, Ed. Operator, could we now please move to Q&A?

Jared Haase analyst
#4

Hey, everyone. Appreciate you letting us ask questions. I suppose I'll begin with the revised guidance you just gave. I wanted to nail down the details a bit. What exactly shifted in the way you view how this year will play out versus the last time you reported, back in March? I'm wondering what portion of the changed revenue outlook you'd chalk up to still encountering slower decision-making among pharma customers, versus those choices now being made but with a smaller spending commitment in 2026 than what you might have expected at that earlier point. With that in mind, is there a way to frame how much visibility you actually have right now under the new guidance?

Steve Silvestro executive
#5

Hey, Jared. Appreciate the question. I'll handle this one, and then Ed and Andy may want to add something. What we had back in March, I think, was early visibility into where we believed the year might inflect following Q1, at which point we'd gain greater sight into the second half. In particular, we had a small number of customers responding to the administration's stance on MFN and how that affected the way they managed budgets. After their first reaction, several of them have in fact returned and returned with more strength, despite shorter contract duration periods. I believe we've said that in public. We mentioned it on the previous earnings call, and we mentioned it once more this time. There's one notably bigger customer where disruption persists. When we discuss asynchronous disruption at the level of a single client, and one of this magnitude, we have to push through it. That simply leaves us with reduced visibility into the full year guide, which explains why we're leaning somewhat more conservative and bringing it back to where we feel confident we'll end up. My expectation isn't that another adjustment will be necessary, but we're providing the best picture available to us at this moment.

Jared Haase analyst
#6

Okay; that's helpful.

Steve Silvestro executive
#7

Andy, anything?

Andy D'Silva analyst
#8

No, I think you got it covered. Yeah.

Jared Haase analyst
#9

All right, that's useful. So, I suppose you're describing it as pressure over the short to intermediate term. I'm not sure whether there's a way to pin down precisely what you're getting at with that. As we consider.

Steve Silvestro executive
#10

Yes.

Jared Haase analyst
#11

We're near the close of the year, and I'm wondering — does this carry over into 2027, or is your sense that it stays within this year?

Steve Silvestro executive
#12

No, our view is that it stays within this year. What's real is that we might observe, you know, further along in Q3, and then in Q4, more purchasing activity from that group of customers, and especially a single customer where there was disruption. As we see it right now, disruption will continue through the close of 2026. When we look at 2027, nothing is mechanically broken in any of those businesses, and definitely not in ours, as the wider gross margin shows, and simply from how we run things with greater leverage and drop through, retiring the debt, improving it, bringing interest expense down. From an operational standpoint, it has never been better. We are telling you what's happening with the top line, as one, you know, as we ought to. We fully believe 2027 will be quite spectacular. Regarding the link to the DSPs, you saw the announcement about that — it's a huge matter for this business. It's something we've spent a number of years on. Nobody else has really connected at scale to this ecosystem before us, and we're quite enthusiastic about what it means for the top line and for our clients who are heading toward purchasing in this manner. We're, we're thrilled for the entire team.

Jared Haase analyst
#13

All right, that's encouraging. I'll just stop here and rejoin the queue.

Steve Silvestro executive
#14

Appreciate it, Jared.

Jeff Garro analyst
#15

Good afternoon, and thanks for taking my question. I wanted to dig a bit deeper into the MFN disruption, and perhaps more specifically into what you've said regarding how long contracts are running. I suppose that ties into visibility overall. I believe on the last call you mentioned that contracted revenue sat roughly 15%-20% below the prior year's level, once you set aside managed services; the main reason being that customers were shifting toward shorter contract terms. I'm curious what you observed during the first quarter, and even across April and into May, regarding that renewal behavior among clients, their appetite for extending duration on renewals, and what you expect for the back half of the year.

Steve Silvestro executive
#16

Yeah. Thanks, Jeff. Great to hear from you. So contracted revenue dropped 15% to 20% during the first half. We're still sitting in that exact range, that same band. Most of it comes from contracts with shorter terms that fall beyond the initial managed service sunset. What usually happens is commitments simply come in shorter than they otherwise would. Normally they'd run six to 12 months, and our contracted revenue approach, as I believe everyone's aware, involves calculating the contract's full value against the backlog. With a shorter contract duration, you get less visibility. What that means is, when the following quarter comes around, you're committed to getting that renewed, and then you have to do the same thing again the quarter after that. So visibility is somewhat reduced. That said, I can tell you that renewals keep happening. Business keeps flowing and moving along. In fact, between our first earnings call and this one, two or three accounts have picked up speed in a big way, which is genuinely encouraging. On the tougher side, Jeff, I believe we still have a single large customer dealing with certain difficulties, and some of those difficulties involve MFN. To be honest, a portion of it comes down to poor execution on our end with that particular account, and we have to get better. We have a decent sense of where we let things slip; we've had productive discussions with their leadership, there's a roadmap in place to right the ship, and our people have really stepped up and taken responsibility as we move ahead. We're quite confident this is a near-term issue; the innovation has us energized, and every one of our partners shares that enthusiasm about the innovation announcements we just rolled out, so we're eager to keep pushing forward. And yes, until we break through, the contracted revenue remains the hurdle.

Jeff Garro analyst
#17

Got it. Thanks for all that context. I've got one additional question. I was hoping to dig into how demand is trending when you break it out by customer size — specifically, the top 20 pharma companies compared with, say, that mid-tier and long-tail group.

Steve Silvestro executive
#18

Yeah

Jeff Garro analyst
#19

Looking at your KPI, it's been dropping as a share of revenue over the past 12 months. Where does that trajectory head next, and how should we frame the sales cycle, rates of renewal, and spending patterns coming out of that mid-tier, long tail group? Thanks.

Steve Silvestro executive
#20

Yeah, sure. Appreciate the questions. You know, internally we're really enthusiastic about the mid-tier long tail. That segment of customers has shown enormous progress; there's now a team dedicated to it; we're beginning to witness some genuinely promising expansion there. We're seeing this too — I think I mentioned it before regarding med tech, and it was in my prepared remarks as well — where clients who essentially weren't customers before, weren't even a segment we addressed, are arriving with, you know, investments of several million dollars in the platform; that has us very, very encouraged; when it comes to the top 20, engagement remains strong, and we are, I'd say, so under-penetrated regarding the brands we serve within the top 20. We do have some kind of presence in every one of those accounts, but the chance to grow where we've already established ourselves is still a massive opportunity for this company; we have a fantastic sales team that holds my complete confidence and trust, and they keep pressing forward and performing well. I fully believe they'll deliver a strong close and get ready for 2027, which is truly what our attention is on at the moment. Thanks, Jeff.

Jeff Garro analyst
#21

Thanks, everyone.

David Grossman analyst
#22

Appreciate it. Good afternoon. Steve, I've got a question. It seems like a single client might be down more, or perhaps is having an unusually large effect on your growth rate for this year. Is there something distinctive about what that client is dealing with, or was that the very same client where you had some execution problems?

Steve Silvestro executive
#23

No, we're talking about the same client there. And honestly, David, it's wonderful to hear from you. Looking forward to meeting up next week, or the one after. Frequently, situations arise asynchronously on the client side — an agency gets replaced, a team gets replaced, there's staff churn, decisions get made by new people. We've talked enough over time that you're aware this is a common occurrence in our industry, and it's simply something you have to navigate. DAAP's expansion of 60%, and in particular the 45% increase on the subscriptive side, is intended to smooth out that unevenness, and it is clearly working. This particular DAAP client wasn't one where the disruption occurred, so those were, in effect, bimodal purchases even when volume was large. Whenever there's turbulence within the organization — employee turnover, new people in decision-making roles, and so on — it's difficult, and in that instance we fell short of the execution standard we should have met. We have to get better at it. The encouraging part I can tell you is that we've since met with that leadership team, had very candid discussions, received excellent input, and I believe that connection has been reenergized and is going to be in quite a solid position. That said, it's still too soon to include it in our forecasting guide. We need to continue working with that group and ensure we come through.

David Grossman analyst
#24

If we simply figure it follows the usual pattern, does that mean we face pressure across the coming 3 quarters, and after lapping it in March of next year we're basically past it — or might it not play out that way?

Steve Silvestro executive
#25

Yeah, I think so.

David Grossman analyst
#26

Even turn sooner?

Steve Silvestro executive
#27

No, my sense is we will handle that when this year's renewal period comes around. Probably we'll see some purchasing activity from that group during the back half of the year — that's what we're hoping for and aiming at. By 2027, I think we'll be in a strong spot. In the first half, we had to absorb a few hits and fix a bit of how we were working with them, then get things back on track in the second half.

David Grossman analyst
#28

Understood. Alright, I appreciate you being upfront about that. Thanks for that. Now, regarding the DSP side, the linkage into the DSPs — what does that sales cycle look like? How much time is needed before that sort of flywheel gets going with these media buyers, to the point where it can genuinely begin adding to revenue growth in a way substantial enough that we'd actually notice it?

Steve Silvestro executive
#29

Right. I believe we'll begin to witness the early innings of this, probably around the, you know, latter portion of the back half of this year. In Q4, some revenue should begin to come through. As we head into the 2027 renewal cycle, we will see it truly flow. You know, the manner in which the DSPs function is that once a connection exists there, right, it kicks off a bidding system in which agencies — and agencies are the primary parties purchasing within these, you know, within these ecosystems via the demand-side platforms. It'll adhere to that standard brand plan, you know, RFP process, but they possess the capability to speed things up, define the parameters inside these DSP platforms and begin to action buys. Honestly, I'd describe them as passive buys because it's, you know, you're not truly interacting directly with the company beyond establishing the pricing, establishing the bids, posing the questions to the sales team regarding it. The role of our sales team, really, is to keep engaging with those clients and ensure they are making use of those moduses of acquisition, right? Ensure they are purchasing through those DSPs. They're aware it's available, it's in their preferred DSP of choice, and they can go in and action those buys.

David Grossman analyst
#30

Could you provide a few illustrations of how the revenue might shape up? I'm guessing this breaks out by each drug, correct? And by purchaser, right? I'm not really certain how I should be thinking about what this might amount to in terms of—

Steve Silvestro executive
#31

Yes. The top line from this could be enormous. It could be quite substantial, honestly. But I'm not in a position to give you forecasts for it at this point. During the prepared remarks, we mentioned that this represents 80% of all digital spending within the category. That should give you something to work with. I'm aware you have the TAM memorized like the back of your head — the back of your hand, I mean. It's a very big opportunity, David. Calling any revenue figure on it now would be premature, since nobody else has been doing this at scale before us. Other firms have linked up perhaps a single piece of a network or one EHR provider and kind of toyed around with it. Doing it at scale, at our size — we're the first to truly commit fully. We'll be making further announcements as we roll out the partnership agreements, and there's more we'll say about that, but I don't want to get ahead of myself here.

David Grossman analyst
#32

Absolutely. If I may slip in just one more question. Regarding managed services — was there none at all during the quarter, and none in the guidance either? Is that what I heard?

Andy D'Silva analyst
#33

That's correct.

Steve Silvestro executive
#34

Yeah. Thanks, Andy.

David Grossman analyst
#35

Okay. All right, guys. Thanks very much for the time.

Steve Silvestro executive
#36

Thanks, David. Look forward to seeing you.

David Grossman analyst
#37

Same here.

Steve Silvestro executive
#38

Thanks, operator. To wrap up, I'd like to restate how confident we are in the opportunity that lies ahead over the long term. Even as we work through pressure in the near term, the shift occurring in life science toward engagement powered by digital, data-driven methods has us excited, and that trend is both strong and lasting. At the heart of that shift, OptimizeRx holds a position no one else does. Through our network spanning point of care and point of prescribe, paired with our targeting abilities built on data, we can bring value during pivotal moments along the patient journey. And customers will soon be able to access all of it programmatically, purchasing in whatever manner suits them best. As for our priorities, they haven't changed. Our focus is on boosting DAAP utilization, keeping up our move toward a revenue model that is more predictable and subscription-based, and generating growth that is both sustainable and profitable as time goes on. I'd also like to express thanks to our employees for their ongoing commitment, and to our customers for standing with us as we move through this changing landscape. Thanks once more for spending time with us today. We can't wait to talk with you at the investor conferences coming up and on our next earnings call. Thank you.

Operator operator
#39

Thanks, Mr. Silvestro. To close out today's call, I want to read the safe harbor statement, which lays out important warnings regarding forward-looking statements we've made here. What management has said during this call may contain forward-looking statements, as those are defined by Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended; you shouldn't rely on these forward-looking statements when making investment decisions. Words like anticipate, estimate, expect, possible, and seeking, plus similar expressions, are indicators of forward-looking statements; such statements may speak only as of the date they are made. Statements about what lies ahead appear in this call, covering these topics: how we expect to perform going forward, our expansion initiatives, and the extent to which we penetrate markets; the assumption that macroeconomic conditions and disturbances will not persist; the expectation that engagement built on digital tools and data stays whole and keeps contributing meaningfully to the business; our intentions around generating worth for shareholders; our goal of reaching and holding Rule of 40 status as a company; our aim to bring programmatic access to the company's authenticated EHR network to market without setbacks; the expectation that such programmatic access lifts how much of our inventory gets used; the opening of a revenue channel with strong growth; our capacity to seize a sizable opportunity over the long term; our intentions for expanding the value we create for shareholders; moving a larger share of revenue into a subscription-based structure; managing costs; the projected ranges for 2026 revenue and adjusted EBITDA; technology; investments; avenues for growth; meeting our operating funding requirements along with key strategic priorities; and forthcoming events and announcements. Management's projections for the remainder of the year are included among these forward-looking statements. The company assumes no duty to publicly refresh or amend any forward-looking statements, whether as a result of fresh information, upcoming occurrences, or any other reason. By their very nature, forward-looking statements carry risks and uncertainties, certain of which are impossible to foresee or measure. Actual outcomes and later developments may diverge substantially from those expressed in, envisioned by, or forming the basis of such forward-looking statements. Things that could pose risks or create uncertainty for these forward-looking statements include — though this isn't a complete list — what happens with government regulation, competitive pressure, reliance on a small, concentrated set of customers, cybersecurity events that might interrupt operations, whether the company can stay current with technology that keeps growing and changing, whether it can hold onto its contracts with electronic prescription platforms and electronic health record networks, plus other significant risks. A fuller picture of the risks and uncertainties that might impact the business and its financial results appears in the company's annual report on Form 10-K covering the year that ended December 31, 2025, along with other documents the company has already filed, and could file later, with the SEC. Once those documents get submitted, you'll be able to find them on both the company's site and the SEC's site, sec.gov. As we wrap up this call, a quick note: a replay of today's audio will be up later tonight, and it'll stay accessible for twelve months in the investor area of the company's website. Thanks for being with us. That brings today's call to a close. You're free to hang up now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete OptimizeRx Corporation transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to OptimizeRx Corporation earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.